Cutaneous Eruption due to Telaprevir

Hepatitis C virus (HCV) chronically infects 0.5–3% of the world population. A large group of patients develop cirrhosis and its complications. Since 2011, telaprevir and boceprevir are used, improving the disease evolution. One of the main side effects of these drugs is skin eruption. We report a 53...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcão, Eduardo Mastrangelo Marinho, Trope, Beatriz Moritz, Godinho, Mariana Marteleto, Carneiro, Leonardo Hoehl, de Araujo-Neto, João Marcello, Nogueira, Cristiane Alves Villela, Ramos-e-Silva, Marcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Published online: September, 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612548/
https://www.ncbi.nlm.nih.gov/pubmed/26500538
http://dx.doi.org/10.1159/000439264
Descripción
Sumario:Hepatitis C virus (HCV) chronically infects 0.5–3% of the world population. A large group of patients develop cirrhosis and its complications. Since 2011, telaprevir and boceprevir are used, improving the disease evolution. One of the main side effects of these drugs is skin eruption. We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with telaprevir. In the ninth week, he presented a severe rash that required the interruption of this drug. We emphasize the importance of early recognition and appropriate management of adverse skin reaction.

Ejemplares similares